Examkin

Soru

Zorluk: Çok zorCardiovascular System

A 28-year-old woman presents to the clinic with an 8-month history of progressive exertional dyspnea, fatigue, and one episode of syncope while climbing stairs. She has no significant past medical history and takes no medications. Her blood pressure is 110/70 mm Hg, pulse is 88/min, and respirations are 16/min. Pulse oximetry shows 97% on room air. Physical examination reveals clear lungs, a prominent right ventricular heave, and a loud pulmonic component of the second heart sound. There is trace lower extremity edema. A transthoracic echocardiogram demonstrates right ventricular dilation, septal flattening during systole, and an estimated right ventricular systolic pressure of 55 mm Hg. The left ventricular size and systolic function are normal, with no significant valvular abnormalities. Pulmonary function testing and high-resolution computed tomography (HRCT) of the chest are unremarkable.

Arrange the following steps in the most appropriate sequential order for the continued diagnostic evaluation and management of this patient's condition.

  1. 1Perform a radionuclide ventilation-perfusion (V/Q) scan
  2. 2Perform right heart catheterization to measure resting hemodynamics
  3. 3Administer inhaled nitric oxide to assess for acute pulmonary vasoreactivity
  4. 4Initiate therapy with a high-dose oral calcium channel blocker

Cevap

The correct sequence is: (1) Perform a radionuclide ventilation-perfusion (V/Q) scan, (2) Perform right heart catheterization, (3) Administer inhaled nitric oxide, and (4) Initiate therapy with a high-dose oral calcium channel blocker.
The patient's clinical presentation (exertional dyspnea, syncope, loud P2, RV heave) and echocardiogram (estimated RVSP 55 mm Hg, structurally normal left heart) strongly suggest pulmonary hypertension. The diagnostic algorithm for unexplained pulmonary hypertension follows a strict sequence. First, intrinsic lung disease (WHO Group 3) and left heart disease (WHO Group 2) must be excluded, which has been accomplished here with normal HRCT, PFTs, and a normal left ventricle on echo. The next mandatory step is to rule out chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) using a radionuclide ventilation-perfusion (V/Q) scan, which is more sensitive than CT angiography for chronic clots. If the V/Q scan is negative, the diagnosis is likely pulmonary arterial hypertension (PAH, WHO Group 1). Right heart catheterization (RHC) is then performed to definitively confirm PAH (mean pulmonary artery pressure ≥ 20 mm Hg and pulmonary capillary wedge pressure ≤ 15 mm Hg). During the RHC procedure, acute vasoreactivity testing is conducted using a short-acting pulmonary vasodilator (e.g., inhaled nitric oxide). Only if the patient demonstrates a positive acute vasoreactivity response should they be started on a high-dose oral calcium channel blocker. If negative, other advanced therapies (e.g., bosentan, sildenafil) are required.

Adım Adım Çözüm

1
Perform a radionuclide ventilation-perfusion (V/Q) scan.
Screens for chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4).
Before invasive testing, patients with unexplained pulmonary hypertension must be screened for CTEPH, as it is potentially curable with surgical thromboendarterectomy. V/Q scan is the preferred initial screening test because it is more sensitive than CT pulmonary angiography for chronic thromboembolic disease.
2
Perform right heart catheterization to measure resting hemodynamics.
Confirms the diagnosis of pulmonary arterial hypertension.
If the V/Q scan is negative, right heart catheterization (RHC) is the gold standard required to definitively diagnose pulmonary arterial hypertension (PAH). It confirms an elevated mean pulmonary artery pressure (≥ 20 mm Hg) and rules out occult left-sided heart disease by demonstrating a normal pulmonary capillary wedge pressure (≤ 15 mm Hg).
3
Administer inhaled nitric oxide to assess for acute pulmonary vasoreactivity.
Identifies the subset of patients with reactive pulmonary vasculature.
During the RHC, a short-acting vasodilator (such as inhaled nitric oxide, intravenous epoprostenol, or intravenous adenosine) is administered to assess for acute vasoreactivity. A positive response indicates a favorable prognosis and alters the management pathway.
4
Initiate therapy with a high-dose oral calcium channel blocker.
Provides targeted pharmacotherapy for vasoreactive PAH.
Only the small percentage of PAH patients (approx. 5-10%) who demonstrate a positive acute vasoreactivity response during RHC are candidates for a trial of high-dose oral calcium channel blockers. Patients who are not vasoreactive require other advanced therapies (e.g., endothelin receptor antagonists, PDE-5 inhibitors).

Anahtar Kavram

The diagnostic and management algorithm for suspected Pulmonary Arterial Hypertension (PAH)
Tahmini Süre:2m 0s
Bu soruyu puanla

Konular

Cardiovascular System

Bu konudan daha fazla soru